The use of novel agents in the treatment of relapsed and refractory multiple myeloma

被引：63

作者：

Laubach, J. P. ^{[1
]}

Mahindra, A. ^{[2
]}

Mitsiades, C. S. ^{[1
]}

Schlossman, R. L. ^{[1
]}

Munshi, N. C. ^{[1
]}

Ghobrial, I. M. ^{[1
]}

Carreau, N. ^{[1
]}

Hideshima, T. ^{[1
]}

Anderson, K. C. ^{[1
]}

Richardson, P. G. ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Cleveland Clin, Taussig Canc Ctr, Dept Med Oncol, Cleveland, OH 44106 USA

来源：

LEUKEMIA | 2009年 / 23卷 / 12期

关键词：

multiple myeloma; chemotherapy; lenalidomide; thalidomide; bortezomib; PROTEASOME INHIBITOR PS-341; LENALIDOMIDE PLUS DEXAMETHASONE; PEGYLATED LIPOSOMAL DOXORUBICIN; HISTONE DEACETYLASE INHIBITION; BONE-MARROW-TRANSPLANTATION; PREVIOUSLY TREATED PATIENTS; OVERCOMES DRUG-RESISTANCE; LOW-DOSE THALIDOMIDE; EXTENDED FOLLOW-UP; PHASE-II;

D O I：

10.1038/leu.2009.179

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although outcomes for patients with multiple myeloma (MM) have improved over the past decade, the disease remains incurable and even patients who respond well to induction therapy ultimately relapse and require additional treatment. Conventional chemotherapy and high-dose therapy with stem cell transplantation (SCT) have historically been utilized in the management of relapsed MM, but in recent years the immunomodulatory drugs (IMiDs) thalidomide and lenalidomide, as well as the proteasome inhibitor bortezomib, have assumed a primary role in this setting. This review focuses on the role of thalidomide, lenalidomide and bortezomib in relapsed and refractory MM, with additional discussion dedicated to emerging drugs in relapsed MM that may prove beneficial to patients with this disease. Leukemia (2009) 23, 2222-2232; doi:10.1038/leu.2009.179; published online 10 September 2009

引用

页码：2222 / 2232

页数：11

共 50 条

[1] The use of novel agents in the treatment of relapsed and refractory multiple myeloma
J P Laubach
A Mahindra
C S Mitsiades
R L Schlossman
N C Munshi
I M Ghobrial
N Carreau
T Hideshima
K C Anderson
P G Richardson
Leukemia, 2009, 23 : 2222 - 2232
[2] Treatment of relapsed and refractory multiple myeloma in the era of novel agents
van de Donk, Niels W. C. J.
Lokhorst, Henk M.
Dimopoulos, Meletios
Cavo, Michele
Morgan, Gareth
Einsele, Hermann
Kropff, Martin
Schey, Steve
Avet-Loiseau, Herve
Ludwig, Heinz
Goldschmidt, Hartmut
Sonneveld, Pieter
Johnsen, Hans E.
Blade, Joan
San-Miguel, Jesus F.
Palumbo, Antonio
CANCER TREATMENT REVIEWS, 2011, 37 (04) : 266 - 283
[3] Novel Agents for Relapsed and/or Refractory Multiple Myeloma
Thomas, Sheeba K.
Richards, Tiffany A.
Weber, Donna M.
CANCER JOURNAL, 2009, 15 (06): : 485 - 493
[4] Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
Fostier, Karel
De Becker, Ann
Schots, Rik
ONCOTARGETS AND THERAPY, 2012, 5 : 237 - 244
[5] The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies
Moreau, Philippe
SEMINARS IN HEMATOLOGY, 2012, 49 (03) : S33 - S46
[6] DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
Park, Silvia
Lee, Su Jin
Jung, Chul Won
Jang, Jun Ho
Kim, Seok Jin
Kim, Won Seog
Kim, Kihyun
ANNALS OF HEMATOLOGY, 2014, 93 (01) : 99 - 105
[7] DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
Silvia Park
Su Jin Lee
Chul Won Jung
Jun Ho Jang
Seok Jin Kim
Won Seog Kim
Kihyun Kim
Annals of Hematology, 2014, 93 : 99 - 105
[8] Novel treatment approaches for patients with relapsed and refractory multiple myeloma
Sinha R.
Lonial S.
Current Treatment Options in Oncology, 2006, 7 (3) : 246 - 257
[9] Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma
Chehab, Sarah
Panjic, Elyse Hall
Gleason, Charise
Lonial, Sagar
Nooka, Ajay K.
FUTURE ONCOLOGY, 2018, 14 (30) : 3111 - 3121
[10] Treatment of relapsed or refractory multiple myeloma
Maiolino, Angelo
Garnica, Marcia
LEUKEMIA RESEARCH, 2018, 73 : S3 - S3

← 1 2 3 4 5 →